The Governance Gap: Why Healthcare AI Needs New Rules of Engagement
Post Summary
Healthcare AI is advancing quickly, but the rules to ensure its safety, fairness, and reliability are falling behind. While AI tools are helping address physician and nurse shortages, they’re also introducing risks like bias, cybersecurity vulnerabilities, and inconsistent oversight. Current regulations, designed for static medical devices, fail to address the dynamic nature of AI, leaving critical gaps in accountability and patient protection.
Key issues include:
- Outdated regulations: AI systems face fragmented oversight across agencies like the FDA and FTC, with no unified federal law.
- Bias and fairness concerns: AI tools can perpetuate inequities, with no federal "right to explanation" for automated decisions.
- Cybersecurity risks: AI-powered devices and tools are vulnerable to attacks, with outdated frameworks like HIPAA unable to address modern threats.
- State-by-state inconsistencies: Patchwork laws create confusion, with AI tools allowed in some states but restricted in others.
To address these challenges, frameworks like PPTO (People, Process, Technology, Operations) and tools like Censinet RiskOps are emerging as solutions for better governance. These approaches focus on risk assessments, real-time monitoring, and multidisciplinary oversight to ensure AI in healthcare is both effective and safe for patients.
Bottom line: Without stronger governance, healthcare AI risks harming the very patients it aims to help. Immediate action is needed to close these gaps and build trust in this transformative technology.
From Deployment to Oversight: Strengthening AI Risk Management and Patient Safety in Health Care
sbb-itb-535baee
Regulatory Gaps in Healthcare AI
U.S. vs EU Healthcare AI Regulation Comparison
Fragmented Oversight Across Agencies
The United States lacks a unified federal law governing AI. By April 2026, more than 40 AI-related bills had been introduced in Congress since 2023, but none have been enacted [5]. This legislative stalemate has left a regulatory void, with oversight scattered across agencies that only cover narrow aspects of AI in healthcare.
For example, the FDA oversees medical devices, HHS enforces HIPAA privacy rules, and the FTC addresses consumer protection. Yet, none have comprehensive authority over healthcare AI. Between 2019 and 2023, 67% of AI-enabled medical devices were approved via the FDA's 510(k) pathway - a process designed for traditional devices that doesn't mandate extensive post-market monitoring [4]. Only 34% of these devices are subject to explicit post-market surveillance requirements [4].
"We are in a moment where the technology is advancing faster than our legal frameworks, faster than our institutional capacity, and faster than the public's ability to understand what is being done to them." - Dr. Alondra Nelson, former Deputy Director, White House Office of Science and Technology Policy [5]
This fragmented oversight extends to state-level laws. For instance:
- Texas enacted S.B. 815 in September 2025, requiring human oversight for health insurance claim decisions made by AI [2][1].
- Illinois passed H.B. 1806 in August 2025, banning AI from creating mental health treatment plans or directly interacting with patients for therapy [2][1].
- California followed in January 2026 with A.B. 489, which prevents AI from presenting itself as a licensed professional [2][1].
These state-specific rules create a patchwork system where AI tools may be allowed in one state but restricted or banned in another.
The high costs of vetting new algorithms - ranging from $300,000 to $500,000 - further complicate matters. This financial burden often excludes smaller community health systems, creating a divide where large academic medical centers can afford AI governance structures, while smaller hospitals may avoid AI altogether [3].
These gaps in oversight pave the way for issues like algorithmic bias and data security vulnerabilities.
Inadequate Protections Against Algorithmic Bias
Federal regulations in the U.S. do not guarantee a "right to explanation" for automated decisions. Each year, 35 million Americans face significant automated decisions involving credit, housing, or healthcare, often without any meaningful way to challenge or understand the decision [5]. By contrast, the European Union's AI Act, implemented in August 2024, ensures patients have explicit rights to understand and contest algorithmic decisions. The U.S. has no comparable framework.
Federal oversight tends to be reactive rather than proactive. Agencies like the FTC investigate harms only after they occur, rather than establishing safeguards to prevent biased algorithms from being deployed in the first place [5]. This reactive approach leaves patients vulnerable to discriminatory AI systems, which can perpetuate healthcare inequities.
| Feature | United States (Federal) | European Union (EU AI Act) |
|---|---|---|
| Statutory Status | No comprehensive federal law; relies on executive actions [5] | Active since August 2024; phased rollout through 2027 [5] |
| Risk Categorization | Undefined/Sector-specific guidance [5] | Tiered risk categories (Minimal to Prohibited) [5] |
| Patient Rights | No federal "Right to Explanation" [5] | Explicit right to explanation for automated decisions [5] |
| Enforcement | Reactive (FTC/DOJ) [5] | Prospective compliance and impact assessments [5] |
The December 2025 Executive Order promoting a "hands-off" approach to AI regulation has further weakened patient protections. This stance may override stricter state-level safety and bias rules, leaving patients with fewer safeguards [2].
Cybersecurity and Data Privacy Weaknesses
AI's rise also exposes significant cybersecurity and privacy challenges that current frameworks fail to address.
Traditional cybersecurity systems weren't designed for AI-specific threats. For example, synthetic voices and AI-generated content can bypass conventional fraud detection tools, leaving systems vulnerable to exploitation.
HIPAA, written long before AI became prevalent, now obstructs over 82% of AI implementations due to its outdated requirements for data de-identification and patient consent for secondary data use [4]. The law doesn't adequately address how patient information is used for training AI models or the risk of re-identifying de-identified data through AI techniques.
"The incentive structure of commercially deployed AI actively works against safety disclosures - companies that find problems in their models have financial reasons not to publicize them in the absence of legal mandates requiring disclosure." - Gary Marcus, Cognitive Scientist and AI Critic [5]
Post-deployment monitoring is another weak spot. When AI tools are modified or disabled to comply with varying state laws, it becomes nearly impossible to maintain consistent performance metrics across healthcare systems. This lack of reliable monitoring leaves patients exposed to untracked risks, undermining safety and emphasizing the need for stronger governance structures.
Patient Safety and Data Security Threats
The gaps in regulation highlighted earlier have very real consequences for both patients and healthcare organizations. These aren't hypothetical scenarios - they're happening now, with well-documented examples. Here's why the governance frameworks mentioned earlier are urgently needed.
Biased AI Diagnostics and Patient Harm
AI diagnostic tools can fail due to issues like sampling bias, overfitting, and overdependence by clinicians on these systems[7]. These failures are symptoms of an unregulated landscape that allows untested systems to be deployed in care settings.
The results can be devastating. For example, a care-management algorithm underestimated the disease burden of Black patients by 26.3% because it used healthcare spending as a stand-in for medical need. This led to the systematic de-prioritization of patients with historically lower healthcare expenditures[6]. Similarly, dark-skinned melanoma patients faced false-negative rates 28% higher than other groups due to biased training data[7]. In critical care, AI misdiagnosis rates for minority patients were 31% higher compared to majority groups[7].
Distrust of AI also plays a role. Radiologists override accurate AI recommendations 34% of the time because they don't trust the "black-box" nature of these systems. On the flip side, automation complacency slows clinicians down by 41% when it comes to catching errors in human-AI workflows[7].
IBM's Watson for Oncology serves as a cautionary tale. Between 2011 and 2022, IBM poured about $4 billion into this system to generate personalized chemotherapy recommendations. However, internal documents revealed that it often produced "unsafe and incorrect treatment recommendations" because it was trained on hypothetical cases rather than real-world data. By January 2022, IBM had sold off its Watson Health business[6]. Similarly, the Epic Sepsis Model missed two-thirds of patients who eventually developed sepsis during an audit[6].
"Spectacular performance on synthetic tasks does not guarantee reliability at the bedside." - Ryan Sears, American Journal of Healthcare Strategy[6]
AI's flaws aren't limited to diagnostics. Vulnerabilities in AI-powered medical devices add another layer of risk.
Security Risks in AI-Powered Medical Devices
As of 2025, the FDA has authorized over 1,000 AI-powered medical devices[10]. However, these devices often come with significant security weaknesses. Between 53% and 60% of connected medical devices have critical vulnerabilities, while 73% of networked IV infusion pumps contain at least one security flaw[10]. In 2021 alone, healthcare organizations faced an average of 830 cyberattacks per week[10].
AI-based attacks are particularly concerning because they target the integrity of data, not just its confidentiality or availability[9]. For instance, adversarial attacks can introduce tiny, almost invisible changes to medical images, tricking diagnostic models into making incorrect conclusions[10]. Data poisoning is another threat, where malicious samples are added to training datasets, skewing model behavior and leading to biased or unsafe outputs[10]. Prompt injections can bypass AI safeguards, potentially exposing private patient data or causing unintended system actions[9].
"AI-based attacks tend to lean toward integrity-based attacks." - Jeff Crume, Distinguished Engineer, IBM[9]
AI systems operate autonomously and at incredible speed. If compromised, they can carry out harmful actions in minutes - tasks that would take a human attacker much longer to complete[9]. Outdated medical equipment without modern security updates adds to the problem, creating vulnerabilities that the FBI has flagged as an increasing concern[10].
On top of these risks, healthcare organizations' reliance on third-party AI vendors introduces even more complexity.
Third-Party AI Vendor Risks
Healthcare providers are increasingly turning to third-party AI vendors, many of which operate as opaque "black-box" systems. This lack of transparency makes independent validation almost impossible and introduces new risks in the absence of strong governance.
For example, fine-tuning large language models with clinical data raises questions about where Protected Health Information (PHI) ends up after training and whether these models can be manipulated to reconstruct sensitive patient data. Vendor infrastructure may also fail to meet HIPAA Security Rule standards, especially during intermediate processing stages where PHI could be exposed to unauthorized individuals.
Another issue is classification drift. AI tools initially designed as exempt Clinical Decision Support systems can unintentionally shift into the category of unapproved medical devices if their usage changes, creating regulatory and liability challenges[11]. Every patient query processed by a third-party AI system generates a trail of PHI that requires automated logging and strict access controls - tasks that traditional manual systems can't handle.
"Shadow AI" is another growing concern. This refers to clinicians using unapproved generative AI tools to cope with burnout, operating entirely outside institutional oversight[8]. Similarly, "shadow data" involves sensitive patient information being moved to unsecured environments for AI experimentation, bypassing established safeguards[9]. Without a Software Bill of Materials (SBOM), organizations have no way to track or fix vulnerabilities inherited from third-party libraries or models[10].
PPTO Framework for AI Governance
When it comes to managing the complexities of AI in healthcare - like biased diagnostics, vulnerable systems, and unclear vendor practices - a clear framework is essential. The People, Process, Technology, and Operations (PPTO) framework provides healthcare organizations with a structured way to govern AI effectively, while still allowing room for innovation.
Duke Health offers a great example of this framework in action. In 2021, they launched a formal AI governance committee based on PPTO principles. Since then, the Duke Institute for Health Innovation (DIHI) has rolled out over 50 AI products. Their governance model is built around four specialized subcommittees: Implementation and Monitoring, Quantitative Assessment, Ethics and Legal, and Operations. For instance, the Quantitative Assessment Subcommittee handles statistical evaluations to ensure AI tools meet performance standards, while the Ethics and Legal Subcommittee tackles issues like algorithmic bias and regulatory compliance [12].
"The integration of human resources, processes, and technology is essential in healthcare... to ensure ethical, effective, and equitable AI adoption." - npj Digital Medicine [12]
Tailored Governance Based on Risk Levels
The PPTO framework categorizes AI tools into two groups: "Limited" or "Full" governance, depending on their risk levels. High-risk tools, like diagnostic algorithms, go through rigorous oversight throughout their lifecycle. In contrast, low-risk tools, such as administrative automation, follow a more streamlined review process. A critical element here is executive sponsorship. Leaders just below the CEO level oversee governance efforts and secure funding - typically 10% to 15% of the total AI budget - to ensure these systems are sustainable over time [12].
Clearly Defined Roles and Responsibilities
For the PPTO framework to work, assigning clear roles is non-negotiable. A strong AI governance committee needs a multidisciplinary team, including clinicians, data scientists, ethicists, legal advisors, and IT professionals. Duke Health’s subcommittees split responsibilities as follows:
- Implementation and Monitoring: Oversees deployment and tracks real-world outcomes.
- Quantitative Assessment: Conducts statistical validations to prevent model drift.
- Ethics and Legal: Reviews AI tools for fairness and regulatory compliance.
- Operations: Manages budgets, timelines, and coordination across departments [12].
Rotating committee members regularly can also bring in fresh perspectives and prevent any single group from dominating decisions. Research across six U.S. health systems highlights that AI governance is resource-intensive, making efficient role allocation even more critical [15].
Risk Assessment Processes
Not all AI tools require the same level of scrutiny, and the PPTO framework reflects this by implementing a systematic registration process. Every AI tool - whether developed in-house or purchased from vendors - must be registered with the governance committee. This creates a centralized inventory and assigns each tool a risk profile: "Limited" or "Full" governance.
- Limited governance applies to low-risk tools, such as non-clinical decision support.
- Full governance is reserved for high-risk tools like diagnostic systems, which undergo thorough reviews at multiple stages of their lifecycle [12].
In 2024, Trillium Health Partners worked with Duke University Health System to implement the PPTO framework, co-developing workflows that balanced safety with efficiency [14][15].
"The hospitals that struggle are typically the ones who try to build a complete framework before deploying a single tool, or who deploy tools before building any governance at all." - Teresa Younkin & Jim Younkin, Mosaic Life Tech [15]
The framework also establishes clear boundaries. While departments can independently choose low-risk tools, the central governance committee has final say on high-risk systems [12].
Technology Infrastructure for Monitoring
A solid technical foundation is key to effective AI governance. The PPTO framework outlines two critical environments:
- Development Environment: Provides secure data pipelines, tools for model training, and capabilities to assess bias.
- Validation Environment: Integrates with electronic health records (EHRs) to monitor clinical outcomes and detect performance drift in real-time [13].
An AI DevOps approach supports continuous monitoring through automated dashboards that flag anomalies. IT departments play a vital role here, offering data analysis and model monitoring as standard services. The Health AI Partnership (HAIP), which includes over 35 healthcare organizations and federal agencies, has helped shape these capabilities [12]. This infrastructure ensures ongoing risk management and smooth integration of AI tools into clinical workflows.
Tracking Governance Effectiveness
Measuring the success of AI governance is just as important as implementing it. Key performance indicators (KPIs) help track safety, efficiency, and adaptability. Examples include:
- Safety and effectiveness: Number of AI tools showing performance drift or documented clinical impact.
- Efficiency: Time taken from AI registration to approval.
- Adaptability: Frequency of policy updates and completion rates for training.
Duke Health’s governance committee reviews these metrics quarterly. This routine evaluation helps identify bottlenecks, refine processes, and demonstrate the value of governance to leadership [12][13].
Censinet RiskOps for AI Governance
Censinet RiskOps™ builds on the PPTO framework to enhance AI governance by streamlining risk management through automation, while still maintaining crucial human oversight. By combining automated assessments with continuous monitoring, it addresses key challenges in AI governance.
Automated AI Risk Assessments with Censinet AITM
Manual vendor assessments often create delays that hinder AI adoption. To solve this, Censinet AITM (AI Third-Party Management) automates evaluations in line with NIST AI RMF and HIPAA standards. The platform rapidly processes contracts, questionnaires, and evidence documents, completing tasks in minutes.
For instance, in a case study involving a large U.S. hospital network, Censinet AITM automated assessments for over 50 AI diagnostic tool vendors. The results were striking: it found bias in 15% of models, cybersecurity vulnerabilities in 20%, and reduced review times from 40 hours to just 4 hours per vendor. Additionally, it ensured FDA compliance for AI-enabled devices. Users typically experience an 80% reduction in assessment time and 95% accuracy in risk scoring.
The platform also tackles shadow AI risks. Using AI Telemetry, it automatically classifies products in an organization's inventory as AI-capable, not AI-capable, or unknown. This proactive approach minimizes unmonitored risks, setting the stage for more comprehensive oversight and integrating seamlessly into human-in-the-loop reviews.
Human Oversight in Automated Workflows
Automation in Censinet RiskOps doesn’t replace human judgment - it enhances it. The platform uses human-in-the-loop workflows, where AI highlights high-risk issues, such as biased training data, and routes them to GRC experts for review. Analysts can validate evidence using integrated audit trails and override AI decisions when needed. This process ensures accountability in 98% of automated workflows.
In February 2026, Censinet introduced Censinet GRC AI™ at the ViVE conference in Los Angeles. This platform includes seven specialized AI agents, such as the Assessor Agent for supply chain risk. The Assessor Agent automates tasks like capturing technical integration details, generating findings for Corrective Action Plans, and summarizing SOC2 reports or penetration tests. Risk teams maintain control through configurable rules and review processes, ensuring automation supports critical decision-making rather than replacing it. Real-time dashboards further empower GRC teams to continuously monitor risks.
Real-Time Risk Dashboards for GRC Teams
Static reports fall short in the fast-paced world of AI. Censinet RiskOps dashboards deliver live visualizations of AI risk scores, compliance status, vendor performance, and trends like bias drift or breach alerts. These dashboards allow GRC teams to drill down into specific impacts, such as patient safety, set thresholds for algorithmic audits, and create reports for boards.
The dashboards also feature AI concentration charts, which highlight where AI risks are clustered within the vendor portfolio. If AI Telemetry detects that a vendor has added AI capabilities to an approved product, GRC teams can immediately launch AI-specific assessments from the product profile. This approach effectively addresses gaps that allow shadow AI to go unchecked. Enterprise users report a 70% improvement in decision-making speed and a 90% boost in audit readiness. A 2025 survey of 200 U.S. health systems revealed that 85% credited Censinet with improved HIPAA AI compliance after implementation.
The platform integrates seamlessly with systems like Epic, Cerner, and ServiceNow via APIs. It pulls real-time data on model performance, feeds risk scores into enterprise GRC platforms, and triggers automated alerts for issues like FDA 510(k) non-compliance in AI medical devices. This creates a centralized hub for managing AI-related policies, risks, and tasks efficiently.
Implementation Strategies and Standards
To bridge the governance gap in healthcare AI, practical strategies and globally accepted standards play a key role in ensuring safe and effective implementation.
Creating AI Governance Committees
A strong governance approach starts with forming a multidisciplinary committee. This team should include clinical providers, AI specialists, ethicists, legal advisors, patient representatives, and data scientists [17][12]. Such diversity minimizes blind spots and ensures decisions align with both technical capabilities and patient care priorities.
An example of this in action is Duke Health, which has maintained an institutional AI governance committee since 2021 [12]. To ensure focused oversight, the committee is divided into four subcommittees: Implementation and Monitoring, Quantitative Assessment, Ethics and Legal, and Operations [12]. Each group handles distinct responsibilities, from technical validation to regulatory compliance.
Leadership is key. An executive sponsor, positioned just below the CEO, should oversee the committee, manage coordination, and align activities with organizational goals [12]. Rotating the committee's membership regularly brings in fresh expertise and prevents the concentration of authority, which is especially important as AI technologies continue to evolve [12].
Every AI tool must be registered with the committee. This process keeps an updated inventory and determines whether tools require minimal oversight (for low-risk applications) or comprehensive lifecycle reviews (for high-risk systems) [12]. Budgeting is another critical element - allocating a portion of AI spending to governance ensures the system remains supported [12].
This structured committee model lays the groundwork for integrating ethical principles and global frameworks into AI governance.
Applying WHO and Industry Standards
Internal governance efforts are strengthened by adhering to global standards, which enhance both accountability and safety.
The World Health Organization (WHO) has outlined six core ethical principles for healthcare AI: protecting autonomy, promoting well-being, ensuring transparency, fostering accountability, ensuring equity, and supporting sustainable AI [18]. These principles become actionable when paired with technical frameworks.
"Ethical considerations, human rights, and principles of equity must be paramount and central to every stage of the design, development, deployment, and evaluation of AI technologies for health." - World Health Organization [18]
WHO's 2024 guidance on Large Multi-modal Models includes over 40 recommendations for managing risks like misinformation and "hallucinations" in healthcare AI [18]. Organizations can combine these guidelines with frameworks such as the ITU-WHO Focus Group on Artificial Intelligence for Health (FG-AI4H) to create standardized benchmarks for clinical AI use [18].
The Health AI Partnership (HAIP) network, which includes over 35 healthcare organizations and federal agencies, collaborates to establish shared AI standards [12]. Participating in such networks helps organizations stay updated on emerging practices and regulatory requirements. Additionally, mandatory post-release audits and impact assessments, especially for generative AI tools, help identify performance issues before they affect patient safety [18].
PPTO Framework Implementation Analysis
The PPTO framework offers a structured approach to AI governance, focusing on four key domains: People, Process, Technology, and Operations. Here's a breakdown of its strengths and challenges:
| Domain | Advantages | Disadvantages/Challenges |
|---|---|---|
| People | Brings together multidisciplinary expertise and ensures human oversight; reduces bias [12]. | Requires significant time commitment and continuous education to keep up with AI advances [12]. |
| Process | Provides a clear roadmap for the AI lifecycle; standardizes risk assessments and approvals [12]. | Can slow down innovation if the registration and review process becomes too lengthy [12]. |
| Technology | Builds the infrastructure needed for real-time validation and secure environments [12]. | Demands high upfront costs for hardware, software, and data management systems [12]. |
| Operations | Focuses on sustainability, budget planning, and executive accountability [12]. | Adds administrative complexity and requires a dedicated budget for governance [12]. |
"The PPTO framework helps HDOs identify and develop the foundational capabilities needed to achieve compliance, implement responsible AI practices, and operationalize external standards in a way that is structured, efficient, and sustainable." - npj Digital Medicine [12]
This framework strikes a balance between innovation and oversight. For instance, the Duke Institute for Health Innovation has successfully developed over 50 AI products in the past decade using these principles [12]. Organizations can evaluate their governance maturity using a four-level scale: Initial (exploratory), Developing (informal), Defined (formalized), and Sustained (fully established with continuous improvement) [12]. This self-assessment helps pinpoint gaps and prioritize investments in governance systems.
Conclusion
Key Points for Decision-Makers
The lack of strong governance in healthcare AI is more than a policy issue - it’s a direct threat to patient safety. Decision-makers are grappling with three major hurdles: fragmented oversight among agencies like the FDA and HHS, which leaves AI systems without clear regulation; insufficient safeguards against bias, leading to discriminatory outcomes; and cybersecurity vulnerabilities that expose patient data, with breaches costing U.S. providers an average of $10.1 million in 2024 [19]. These gaps in oversight and protection put patients at considerable risk.
The PPTO Framework provides a clear roadmap to address these issues. It outlines steps for defining roles, conducting risk assessments, setting up monitoring systems, and tracking performance [19][21]. For instance, the Mayo Clinic demonstrated how structured oversight reduced algorithmic bias in diagnostics by 35% [21]. Similarly, Censinet RiskOps simplifies the process by automating AI risk assessments through Censinet AI™, integrating human oversight, and offering real-time dashboards for governance and compliance teams [16].
The urgency is backed by data: more than 80% of healthcare AI deployments reveal bias risks, but frameworks like PPTO can cut these incidents by 40–60% [19]. Implementing strong governance isn’t just about compliance - it’s about creating a foundation for innovation that prioritizes patient safety and improves care.
Healthcare leaders must act now to close this governance gap.
Next Steps for Healthcare AI Governance
Immediate action is critical. Within the next 30 days, healthcare organizations should assemble a cross-functional team that includes clinicians, IT specialists, legal advisors, and ethics experts. This team should initiate PPTO risk assessments using tools like Censinet AI™ and compare their practices to WHO’s AI ethics principles and HIMSS guidelines [20].
Set measurable goals: aim for bias detection rates below 5%, reduce cybersecurity incidents by 20% year-over-year, and evaluate governance maturity through PPTO audits. Use real-time dashboards to ensure continuous improvement [19]. Without these structured frameworks, the risks will persist. Only by defining clear roles, leveraging automated tools, and committing to strong leadership can healthcare AI be both safe and ethical for patients.
FAQs
Who is accountable when healthcare AI harms a patient?
Accountability primarily rests on the shoulders of clinicians and institutions that utilize and oversee AI systems. Alongside them, technology vendors who design and develop these systems also share responsibility. To maintain patient safety and clarify liability, establishing clear governance structures and strong oversight mechanisms is absolutely critical.
How can hospitals detect and prevent AI bias after deployment?
Hospitals can tackle AI bias even after deployment by focusing on continuous monitoring, validation, and governance. This involves routinely evaluating how AI performs across various patient groups to identify and address potential biases. Using AI-specific governance tools can help automate bias detection, making the process more efficient.
Another crucial step is forming cross-functional oversight teams. These teams should include experts from clinical, IT, and compliance fields to ensure transparency and accountability throughout the system's lifecycle. By combining these efforts with ongoing validation and proactive governance, hospitals can work toward maintaining fairness and safety in their AI-driven healthcare systems.
What’s the fastest way to govern third-party AI tools without slowing care?
The quickest path to managing third-party AI tools while ensuring uninterrupted care delivery lies in continuous monitoring and strong risk management frameworks designed specifically for AI systems. Prioritize AI-focused governance methods, such as real-time performance tracking, automated oversight mechanisms, and well-defined contractual terms that address liability, transparency, and data ownership. Establishing cross-functional oversight committees can also help maintain accountability and ensure these tools integrate smoothly into clinical workflows without causing disruptions.
